Memorandum submitted by Dr Jean Monro and Dr Peter Julu HO 20








1 Homoeopathic dilutions resemble dilutions of antigens made for low-dose immunotherapy.


2 Allergy is evinced by autonomic changes which are physiologically demonstrable and measurable using the NeuroScope.


3 Low-dose immunotherapy can reverse dysautonomia. This has been demonstrated before and after depictions of physiological abnormalities.


4 Homoeopathic dilutions have been shown to mirror the provocation and nullification of symptoms in different dilutions which are evinced by low-dose immunotherapy dilutions.


5 The lymphocyte sensitivity test is described. It shows sensitivity of lymphocyte membranes when exposed to agents to which the patient is sensitive.


6 Low-dose immunotherapy can stabilise lymphocyte membranes and abort abnormal cell membrane responses, hence controlling symptoms of sensitivity.


7 The findings described have been published, in the first instance, in a peer-reviewed publication and, subsequently as presented to the Joint International Neurogastroenterology and Motility Conference held in Chicago in August 2009.


8 Ongoing studies and observations corroborating these findings have been undertaken and are in the process of being collated.


9 There is clear, scientific evidence of the mode of action of sensitivities, allergies through the autonomic nervous system, which is the neural pathway of allergy and its control through low-dose immunotherapy.


10 As low-dose immunotherapy and homoeopathy are showing parallel effects, the findings in relation to low-dose immunotherapy are relevant to homoeopathy.









I am the Medical Director of Breakspear Hospital. I have a background in hospital general medicine and worked at the National Hospital for Nervous Diseases, Queen Square, London, researching migraine and multiple sclerosis. I entered full time practice in Environmental Medicine in 1982 and in 1988 established the Breakspear Hospital for Allergy and Environmental Medicine. I have also been a Consultant at Fachkrankenhaus Nordfriesland, Germany from 1991 to 2009.


I have many publications to my name and regularly speak at conferences worldwide. My primary areas of interest are nutritional medicine and immunology, metabolic function and environmental medicine.



Peter Julu

Dr Peter Julu is currently a Consultant Physician and Consultant Autonomic Neurophysiologist at Breakspear Hospital in Hemel Hemstead, and a Consultant Researcher at the Institute of Communication in Aalborg University, Denmark. He is the Neurophysiologist in charge at the Swedish National Rett Centre at Frösön Sweden, an Honorary Consultant Autonomic Neurophysiologist at the Royal London Hospital, and an Honorary Senior Clinical Lecturer at both the Wingate Institute of Neurogastroenterology and the Royal London Hospital.

Dr Julu obtained his first medical degree in 1978 from Makerere University, Kampala in Uganda, where he practiced general medicine. He won a highly competitive Commonwealth Scholarship that allowed him to come to London in 1982 for postgraduate studies. In London, he studied Neurophysiology jointly at University College London and the Institute of Neurology in Queen's Square London. In 1986 he was awarded a PhD from the University of London titled "The pathophysiology of diabetic neuropathy". Dr Julu went to Zimbabwe in 1987 as an expatriate Commonwealth Lecturer in the Department of Medical Physiology in the University of Zimbabwe, Harare, and was awarded Life Member of the International Diabetes Federation in 1989. He returned to the United Kingdom in 1990 as a Lecturer in Clinical Neurophysiology in the Department of Neurology at the Institute of Neurological Sciences of Glasgow University, and won the Cormie Prize for Neurology research. He then became a Senior Clinical Research Fellow of Imperial College London in 1998. He has initiated, set up, and successfully run Autonomic Laboratories in Harare Zimbabwe, Glasgow, and at the Central Middlesex Hospital. In recognition of his clinical expertise and research contributions, the Joint Committee on Higher Medical Training (JCHMT) recommended to the Specialist Training Authority that he be accredited the medical specialty of Autonomic Neurophysiology. In 2005, he was registered by the GMC as a Specialist Autonomic Neurophysiologist. The aims of the JCHMT for this accreditation is that such a new specialty will grow around a pioneering practitioner, and this is reflected in Dr Julu's broad research interests in the field of Autonomic Neurophysiology.

Research interests:

· Interactions between the autonomic nervous system and disease processes

· Non-invasive brainstem autonomic neurophysiology; he has invented and patented a machine called the NeuroScope for continuous and real time monitoring of brainstem autonomic functions

· Brainstem function in Rett syndrome - he is an active member of RettSearch, an international consortium of Rett syndrome clinical researchers.


Julu P. Vagolytic effect of diabetes mellitus. Brain 1993; v 116: pp 485-92.

Delamont RS, Julu PO, Jamal GA. Changes in a measure of cardiac vagal activity before and after epileptic seizures. Epilepsy Res 1999; v 35: pp 87-94.

Jamal GA, Hansen S, Julu PO. Low level exposures to organophosphorus esters may cause neurotoxicity. Toxicology 2002; v 181-182: pp 23-33.

Julu PO, Cooper VL, Hansen S, Hainsworth R. Cardiovascular regulation in the period preceding vasovagal syncope in conscious humans. J Physiol 2003; v 549: pp 299-311.

Julu PO, Witt Engerstrom I. Assessment of the maturity-related brainstem functions reveals the heterogeneous phenotypes and facilitates clinical management of Rett syndrome. Brain Dev 2005; v 27 (Suppl 1): S43-53.





There is further information in relation to homoeopathy which can be provided, as work has been undertaken with Dr Cyril Smith, Honorary Senior Lecturer (Retired) at Salford University.




We would like to invite the Committee to support the scientific basis of homoeopathy, as evinced in these observations.



November 2009